<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956487</url>
  </required_header>
  <id_info>
    <org_study_id>116371</org_study_id>
    <nct_id>NCT01956487</nct_id>
  </id_info>
  <brief_title>Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites</brief_title>
  <official_title>A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (Propafenone Hydrochloride) Manufactured at Two Different Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence of propafenone hydrochloride capsules manufactured at two different sites&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase 1, randomized, open-label, single-dose, three-period, crossover study to&#xD;
      assess the bioequivalence of propafenone hydrochloride manufactured at two different sites in&#xD;
      healthy adult volunteers. Approximately 36 subjects will receive a 3 single doses of&#xD;
      propafenone hydrochloride 425mg, each administered separately, in the fasted state with a 7&#xD;
      day washout period between doses. Propafenone hydrochloride is an antiarrhythmic indicated to&#xD;
      prolong the time to recurrence of symptomatic atrial fibrillation in patients with episodic&#xD;
      (most likely paroxysmal or persistent) atrial fibrillation who do not have structural heart&#xD;
      disease. A follow-up visit will occur 7-10 days after the final dose of study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 11, 2012</start_date>
  <completion_date type="Actual">June 27, 2012</completion_date>
  <primary_completion_date type="Actual">June 27, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequvalence</measure>
    <time_frame>48 hours</time_frame>
    <description>Two formulations of propafenone hydrochloride</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
    <description>Plasma AUC and Cmax of propafenone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>48 hours</time_frame>
    <description>Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Arrhythmia, Cardiac</condition>
  <arm_group>
    <arm_group_label>Propafenone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label comparison of 2 formulations</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propafenone</intervention_name>
    <description>Comparison of drug from 2 manufacturing sites</description>
    <arm_group_label>Propafenone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Body weight greater than or equal to 50kg and BMI within the range 18.5 - 31.0kg/m2&#xD;
             (inclusive).&#xD;
&#xD;
          -  Healthy as determined by a responsible and experienced physician, based on a medical&#xD;
             evaluation including medical history, physical examination, laboratory tests and&#xD;
             cardiac monitoring.&#xD;
&#xD;
          -  AST, ALT, alkaline phosphatase and bilirubin less than or equal to 1.5xULN (isolated&#xD;
             bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin&#xD;
             &lt;35%).&#xD;
&#xD;
          -  A female subject is eligible to participate if she postmenopausal or on a stable&#xD;
             regimine of an approved contracetive&#xD;
&#xD;
          -  Capable of giving written informed consent,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
             result within 3 months of screening.&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen. A minimum list of drugs that will be&#xD;
             screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and&#xD;
             benzodiazepines.&#xD;
&#xD;
          -  A positive test for HIV antibody.&#xD;
&#xD;
          -  History of regular alcohol consumption within 6 months of the study defined as:an&#xD;
             average weekly intake of &gt;14 drinks for males or &gt;7 drinks for females. One drink is&#xD;
             equivalent to 12g of alcohol: 12 ounces (360ml) of beer, 5 ounces (150ml) of wine or&#xD;
             1.5 ounces (45ml) of 80 proof distilled spirits.&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: either 30 days, 5 half-lives or twice the duration of the biological effect of&#xD;
             the investigational product (whichever is longer).&#xD;
&#xD;
          -  The subject has donated blood or blood products in excess of 500mL within a 56 day&#xD;
             period.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary&#xD;
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a&#xD;
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first&#xD;
             dose of study medication, unless in the opinion of the Investigator and GSK Medical&#xD;
             Monitor the medication will not interfere with the study procedures or compromise&#xD;
             subject safety.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy that, in the opinion of the investigator or GSK&#xD;
             Medical Monitor, contraindicates their participation.&#xD;
&#xD;
          -  Pregnant females as determined by positive serum or urine hCG test at screening or&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Lactating females.&#xD;
&#xD;
          -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or&#xD;
             nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
          -  Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days&#xD;
             prior to the first dose of study medication.&#xD;
&#xD;
          -  Unwilling to abstain from alcohol for 48 hours prior to screening and 48 hours prior&#xD;
             to the start of dosing until collection of the final pharmacokinetic sample during&#xD;
             each treatment period.&#xD;
&#xD;
          -  Subjects with a pre-existing condition interfering with normal gastrointestinal&#xD;
             anatomy or motility, hepatic and/or renal function, that could interfere with the&#xD;
             absorption, metabolism, and/or excretion of the study drugs. Subjects with a history&#xD;
             of cholecystectomy, peptic ulceration, inflammatory bowel disease or pancreatitis&#xD;
             should be excluded.&#xD;
&#xD;
          -  The subject's systolic blood pressure is outside the range of 90-140 mmHg, or&#xD;
             diastolic blood pressure is outside the range of 45-90mmHg or heart rate is outside&#xD;
             the range of 55-100bpm for female subjects or 50-100bpm for male subjects.&#xD;
&#xD;
          -  Screening ECG within normal limts for age and gender&#xD;
&#xD;
          -  Evidence of previous myocardial infarction.&#xD;
&#xD;
          -  Any conduction abnormality (including but not specific to left or right complete&#xD;
             bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW]&#xD;
             syndrome, non-sustained or sustained ventricular tachycardia (3 or more consecutive&#xD;
             ventricular ectopic beats), sinus pauses &gt; 3 seconds, or other significant arrhythmia&#xD;
             which, in the opinion of the principal investigator and GSK medical monitor, will&#xD;
             interfere&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>&quot;RYTHMOL is a registered trademark of G. Petrik used under license by Abbott Laboratories.&quot;</citation>
  </reference>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>July 19, 2012</study_first_submitted>
  <study_first_submitted_qc>October 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2013</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>RYTHMOL SR®</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Propafenone</keyword>
  <keyword>Pharmavokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propafenone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>116371</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

